<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; evaluate</title>
	<atom:link href="http://www.tapanray.in/tag/evaluate/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Alarming Incidence of Cancer: Fragile Infrastructure: Escalating Drug Prices</title>
		<link>http://www.tapanray.in/alarming-incidence-of-cancer-fragile-infrastructure-escalating-drug-prices/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=alarming-incidence-of-cancer-fragile-infrastructure-escalating-drug-prices</link>
		<comments>http://www.tapanray.in/alarming-incidence-of-cancer-fragile-infrastructure-escalating-drug-prices/#comments</comments>
		<pubDate>Mon, 28 Jul 2014 00:00:38 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2011]]></category>
		<category><![CDATA[2012]]></category>
		<category><![CDATA[2014]]></category>
		<category><![CDATA[alarming]]></category>
		<category><![CDATA[ASCO]]></category>
		<category><![CDATA[Astellas Pharma]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[Biocon]]></category>
		<category><![CDATA[Bristol-Myers Squibb]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[Catering]]></category>
		<category><![CDATA[Celgene]]></category>
		<category><![CDATA[chemicals]]></category>
		<category><![CDATA[Cipla]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[DRL]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Eli Lilly]]></category>
		<category><![CDATA[emcure]]></category>
		<category><![CDATA[escalating]]></category>
		<category><![CDATA[evaluate]]></category>
		<category><![CDATA[fact]]></category>
		<category><![CDATA[Fertilizers]]></category>
		<category><![CDATA[fragile]]></category>
		<category><![CDATA[Glenmark]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[incidence]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[infrastructure]]></category>
		<category><![CDATA[intas]]></category>
		<category><![CDATA[Ipca]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Lancet]]></category>
		<category><![CDATA[Lupin]]></category>
		<category><![CDATA[memorial]]></category>
		<category><![CDATA[Merck & Co]]></category>
		<category><![CDATA[Ministers]]></category>
		<category><![CDATA[Natco]]></category>
		<category><![CDATA[Nexavar]]></category>
		<category><![CDATA[NICE]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[NPPP]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[prices]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reliance Life Science]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[sheet]]></category>
		<category><![CDATA[Sloan]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[Zydus Cadila]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5672</guid>
		<description><![CDATA[According to the &#8216;Fact-Sheet 2014&#8242; of the World Health Organization (WHO), cancer cases would rise from 14 million in 2012 to 22 million within the next two decades. It is, therefore, no wonder that cancers figured among the leading causes &#8230; <a href="http://www.tapanray.in/alarming-incidence-of-cancer-fragile-infrastructure-escalating-drug-prices/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/alarming-incidence-of-cancer-fragile-infrastructure-escalating-drug-prices/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The heated debate on WHO IMPACT definition of Counterfeit Drugs is now on a ‘pause’ – A time to evaluate the reasons for supporting and opposing it.</title>
		<link>http://www.tapanray.in/the-heated-debate-on-who-impact-definition-of-counterfeit-drugs-is-now-on-a-pause-a-time-to-evaluate-the-reasons-for-supporting-and-opposing-it/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-heated-debate-on-who-impact-definition-of-counterfeit-drugs-is-now-on-a-pause-a-time-to-evaluate-the-reasons-for-supporting-and-opposing-it</link>
		<comments>http://www.tapanray.in/the-heated-debate-on-who-impact-definition-of-counterfeit-drugs-is-now-on-a-pause-a-time-to-evaluate-the-reasons-for-supporting-and-opposing-it/#comments</comments>
		<pubDate>Fri, 06 Mar 2009 15:15:50 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[a pause]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[confiscation]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[debate]]></category>
		<category><![CDATA[definition]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[evaluate]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[heated]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[is]]></category>
		<category><![CDATA[now]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[on]]></category>
		<category><![CDATA[opposing]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reasons]]></category>
		<category><![CDATA[supporting]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[time]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=950</guid>
		<description><![CDATA[The World Health Organisation (WHO), in December 2008, proposed the following new definition, as prepared by the International Medical Products Anti-Counterfeiting Taskforce (IMPACT):“A medical product is counterfeit when there is a false representation in relation to its identity and/or source. &#8230; <a href="http://www.tapanray.in/the-heated-debate-on-who-impact-definition-of-counterfeit-drugs-is-now-on-a-pause-a-time-to-evaluate-the-reasons-for-supporting-and-opposing-it/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-heated-debate-on-who-impact-definition-of-counterfeit-drugs-is-now-on-a-pause-a-time-to-evaluate-the-reasons-for-supporting-and-opposing-it/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
